SCHEMBL1629261

SCHEMBL1629261

CC(C)n1cc(-c2ccc(Cl)nc2)c2ccc(NS(C)(=O)=O)cc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 8/20 0.64
NR3C1 P04150 7/20 0.64
NR3C2 P08235 7/20 0.64
AR P10275 6/20 0.60
SCN9A Q15858 5/20 0.52
SCN5A Q14524 3/20 0.52
CYP2C8 P10632 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2B6 P20813 1/20 0.41
CYP2C19 P33261 1/20 0.41
SCN4A P35499 1/20 0.41
SCN2A Q99250 1/20 0.41
KAT2B Q92831 1/20 0.40
MET P08581 2/20 0.39
CLK1 P49759 1/20 0.39
DYRK1A Q13627 1/20 0.39
DYRK2 Q92630 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
ALDH2 P05091 1/20 0.38
MAPK10 P53779 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630751 0.88 PGR (0.66) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1629447 0.87 PGR (0.64) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1631048 0.85 PGR (0.74) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1629973 0.85 PGR (0.63) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1630539 0.85 PGR (0.62) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1631496 0.85 PGR (0.61) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1629165 0.85 PGR (0.73) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1633786 0.84 PGR (0.68) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1630826 0.83 PGR (0.74) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1630747 0.83 PGR (0.67) PGRNR3C1NR3C2ARSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979314-B1 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS LILLY CO ELI (US) 2013-01-09 EP disclosed
EP-1979314-B1 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS LILLY CO ELI (US) 2013-01-09 EP disclosed
US-7932284-B2 Indole sulfonamide modulators of progesterone receptors ELI LILLY AND COMPANY (US) 2011-04-26 US disclosed
US-20090069400-A1 Indole Sulfonamide Modulators of Progesterone Receptors ELI LILLY AND COMPANY 2009-03-12 US disclosed
WO-2007087488-A9 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS LILLY CO ELI (US) 2008-08-28 WO disclosed
WO-2007087488-A2 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069400-A1 Indole Sulfonamide Modulators of Progesterone Receptors PGR, NPSR1, PRLHR PGR 1/4885NR3C1 63/4885NR3C2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.